Get the Stockscreener App
74.59
0.48%
-0.3601
Incyte Corp stock is traded at $74.59, with a volume of 988.16K.
It is down -0.48% in the last 24 hours and up +1.91% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$74.95
Open:
$75.37
24h Volume:
988.16K
Relative Volume:
0.55
Market Cap:
$14.44B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
532.78
EPS:
0.14
Net Cash Flow:
$16.80M
1W Performance:
+0.58%
1M Performance:
+1.91%
6M Performance:
+23.72%
1Y Performance:
+30.08%
1-Day Range:
$74.45
$76.96
1-Week Range:
$72.60
$76.96
52-Week Range:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
74.55 | 14.44B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.19 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.49 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Tandem Financial LLC Invests $358,000 in Incyte Co. (NASDAQ:INCY) - MarketBeat
3,542 Shares in Incyte Co. (NASDAQ:INCY) Purchased by Chicago Partners Investment Group LLC - MarketBeat
SYM FINANCIAL Corp Buys Shares of 5,386 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte (NASDAQ:INCY) Stock Rating Upgraded by StockNews.com - Defense World
StockNews.com Upgrades Incyte (NASDAQ:INCY) to "Strong-Buy" - MarketBeat
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know - Yahoo Finance
Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR
Incyte (INCY) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Pacer Advisors Inc. Trims Stock Position in Incyte Co. (NASDAQ:INCY) - Defense World
Swedbank AB Sells 98,722 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Janney Montgomery Scott LLC Buys 491 Shares of Incyte Co. (NASDAQ:INCY) - Defense World
Incyte Co. (NASDAQ:INCY) Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
4,500 Shares in Incyte Co. (NASDAQ:INCY) Purchased by Union Bancaire Privee UBP SA - MarketBeat
Nisa Investment Advisors LLC Has $1.56 Million Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
VCI Wealth Management LLC Makes New $1.03 Million Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com
Pancreatic Cancer Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma - Barchart
Nisa Investment Advisors LLC Sells 7,731 Shares of Incyte Co. (NASDAQ:INCY) - Defense World
KBC Group NV Sells 104,419 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Patton Albertson Miller Group LLC Increases Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
SG Americas Securities LLC Grows Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Royal Bank of Canada Reiterates Sector Perform Rating for Incyte (NASDAQ:INCY) - MarketBeat
Royal Bank of Canada Reaffirms "Sector Perform" Rating for Incyte (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: strong pipeline faces patent cliff challenges - Investing.com
Steven H. Stein Sells 12,352 Shares of Incyte Co. (NASDAQ:INCY) Stock - MarketBeat
INCY (Incyte) Growth Rank : 8 (As of Jan. 23, 2025) - GuruFocus.com
Insider Decision Unfolding At Incyte: Matteo Trotta Exercises Options, Resulting In $0 - Benzinga
In A Strategic Move, Christiana Stamoulis Acquires Incyte Stock Options Worth $8K: Enhancing Value - Benzinga
Vijay Iyengar Backs Up Beliefs With A Notable Acquisition Of Incyte Stock Options Worth $5K - Benzinga
PAULA SWAIN Decides To Exercise Options At Incyte Worth $0 - Benzinga
Whalen Wealth Management Inc. Invests $245,000 in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Bought by Crossmark Global Holdings Inc. - MarketBeat
Merit Financial Group LLC Invests $624,000 in Incyte Co. (NASDAQ:INCY) - MarketBeat
Drug Co. Wants To Keep Judge On Alopecia IP Case - Law360
Incyte corp EVP Steven Stein sells shares worth $897,866 By Investing.com - Investing.com Canada
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
William Blair Issues Pessimistic Outlook for Incyte Earnings - MarketBeat
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Incyte Gains 15.3% In A Year: Is There Room For Further Growth? - Barchart
Incyte Gains 15.3% in a Year: Is There Room for Further Growth? - Yahoo Finance
Short Interest in Incyte Co. (NASDAQ:INCY) Decreases By 13.1% - MarketBeat
INCY (Incyte) GF Value Rank : 8 (As of Jan. 20, 2025) - GuruFocus.com
Incyte Co. (NASDAQ:INCY) Shares Sold by Shikiar Asset Management Inc. - MarketBeat
Hennion & Walsh Asset Management Inc. Purchases 11,120 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
What You Need To Know Ahead Of Incyte's Earnings Release - Barchart
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - MSN
Fed. Circ. Urged To Keep Block Of Sun Pharma Alopecia Drug - Law360
Contravisory Investment Management Inc. Has $750,000 Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):